Disappointing News for Uveitis Treatment

Pharmaceutical company, Santen, has been developing a drug, intravitreal sirolimus, to treat noninfectious posterior segment uveitis. Uveitis is a type of eye inflammation, in which the uvea, which is the middle part of the eye that supplies blood to the retina, is damaged. To learn more about uveitis, click here.

Last week, the FDA shared some disappointing news for people who were anticipating a new treatment– the drug wasn’t approved.

To learn more about why this happened and what to expect next, read the source article at healio.com.

What are your thoughts on this announcement? Share your stories, thoughts, and hopes, with the Patient Worthy community!

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email